ARTICLE | Clinical News
TriAb: Phase II
May 24, 1999 7:00 AM UTC
Preliminary data from an ongoing Phase II study showed that TriAb elicited an immune response in 20 of 21 patients. There was no disease progression in 17 patients after a median of four months. Data ...